TrialArthritis & rheumatology (Hoboken, N.J.)2016

Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis.

Désirée van der Heijde et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.